Overview

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(2) 80/20/10mg

Status:
Not yet recruiting
Trial end date:
2021-12-21
Target enrollment:
Participant gender:
Summary
A Clinical Trial to evaluate the Pharmacokinetics and Tolerability of CKD-386(2)
Phase:
Phase 1
Details
Lead Sponsor:
Chong Kun Dang Pharmaceutical